Is XORTX Therapeutics Stock a Good Investment?
XORTX Therapeutics Investment Advice | XRTX |
- Examine XORTX Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research XORTX Therapeutics' leadership team and their track record. Good management can help XORTX Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact XORTX Therapeutics' business and its evolving consumer preferences.
- Compare XORTX Therapeutics' performance and market position to its competitors. Analyze how XORTX Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if XORTX Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about XORTX Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in XORTX Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if XORTX Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine XORTX Therapeutics Stock
Researching XORTX Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 2.32. The company has Price/Earnings (P/E) ratio of 170.67. XORTX Therapeutics last dividend was issued on the January 31, 2014. The entity had 1:9 split on the 14th of November 2023.
To determine if XORTX Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XORTX Therapeutics' research are outlined below:
| XORTX Therapeutics generated a negative expected return over the last 90 days | |
| XORTX Therapeutics has high historical volatility and very poor performance | |
| XORTX Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XORTX Therapeutics currently holds about 13.42 M in cash with (6.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| XORTX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: XORTX Therapeutics files to sell 810,810 common shares for holders |
XORTX Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XORTX Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XORTX Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact XORTX Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises XORTX Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.1456 | -0.11 | 0.0356 | 24 | ||
2023-03-31 | 2022-12-31 | -0.27 | -0.2 | 0.07 | 25 | ||
2022-05-12 | 2022-03-31 | -0.19 | -0.26 | -0.07 | 36 | ||
2022-08-11 | 2022-06-30 | -0.24 | -0.12 | 0.12 | 50 | ||
2023-11-14 | 2023-09-30 | -0.19 | -0.67 | -0.48 | 252 | ||
2023-08-14 | 2023-06-30 | -1.36 | -0.8 | 0.56 | 41 | ||
2021-11-29 | 2021-09-30 | -0.0722 | -0.6957 | -0.6235 | 863 | ||
2024-05-15 | 2024-03-31 | -0.2767 | 1.3504 | 1.6271 | 588 |
Know XORTX Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XORTX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XORTX Therapeutics backward and forwards among themselves. XORTX Therapeutics' institutional investor refers to the entity that pools money to purchase XORTX Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-09-30 | 18.8 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.2 K | Royal Bank Of Canada | 2024-09-30 | 672 | Hartland & Co | 2024-09-30 | 277 | Jpmorgan Chase & Co | 2024-09-30 | 254 | Tower Research Capital Llc | 2024-09-30 | 84.0 | Bank Of Montreal | 2024-06-30 | 0.0 | Bmo Capital Markets Corp. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
XORTX Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.34 M.Market Cap |
|
XORTX Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.94) | (0.89) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.47) | (0.49) |
Determining XORTX Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if XORTX Therapeutics is a good buy. For example, gross profit margin measures XORTX Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of XORTX Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in XORTX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XORTX Therapeutics. Check XORTX Therapeutics' Beneish M Score to see the likelihood of XORTX Therapeutics' management manipulating its earnings.
Evaluate XORTX Therapeutics' management efficiency
XORTX Therapeutics has return on total asset (ROA) of (0.3314) % which means that it has lost $0.3314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2936) %, meaning that it created substantial loss on money invested by shareholders. XORTX Therapeutics' management efficiency ratios could be used to measure how well XORTX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to rise to -0.89 in 2024. At this time, XORTX Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 189 K in 2024, whereas Total Assets are likely to drop slightly above 5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.09 | 1.66 | |
| Tangible Book Value Per Share | 3.00 | 3.15 | |
| Enterprise Value Over EBITDA | (0.36) | (0.38) | |
| Price Book Value Ratio | 0.94 | 0.89 | |
| Enterprise Value Multiple | (0.36) | (0.38) | |
| Price Fair Value | 0.94 | 0.89 | |
| Enterprise Value | 2.3 M | 2.2 M |
Understanding the operational decisions made by XORTX Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta (0.21) |
Basic technical analysis of XORTX Stock
As of the 3rd of December, XORTX Therapeutics maintains the Standard Deviation of 7.38, market risk adjusted performance of (1.66), and Mean Deviation of 5.19. In relation to fundamental indicators, the technical analysis model lets you check available technical drivers of XORTX Therapeutics, as well as the relationship between them.XORTX Therapeutics' Outstanding Corporate Bonds
XORTX Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XORTX Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XORTX bonds can be classified according to their maturity, which is the date when XORTX Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand XORTX Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing XORTX Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.66) | |||
| Mean Deviation | 5.19 | |||
| Coefficient Of Variation | (926.74) | |||
| Standard Deviation | 7.38 | |||
| Variance | 54.39 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.91) | |||
| Treynor Ratio | (1.67) | |||
| Maximum Drawdown | 39.16 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.1511 | |||
| Kurtosis | 2.24 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.66) | |||
| Mean Deviation | 5.19 | |||
| Coefficient Of Variation | (926.74) | |||
| Standard Deviation | 7.38 | |||
| Variance | 54.39 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.91) | |||
| Treynor Ratio | (1.67) | |||
| Maximum Drawdown | 39.16 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.1511 | |||
| Kurtosis | 2.24 |
Consider XORTX Therapeutics' intraday indicators
XORTX Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of XORTX Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
XORTX Therapeutics time-series forecasting models is one of many XORTX Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XORTX Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
XORTX Stock media impact
Far too much social signal, news, headlines, and media speculation about XORTX Therapeutics that are available to investors today. That information is available publicly through XORTX media outlets and privately through word of mouth or via XORTX internal channels. However, regardless of the origin, that massive amount of XORTX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of XORTX Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of XORTX Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to XORTX Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive XORTX Therapeutics alpha.
XORTX Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards XORTX Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
XORTX Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| Charlotte May | Corporate Secretary | Profile | |
| MRCP MD | Chief Officer | Profile | |
| David MacDonald | Consultant Operations | Profile | |
| Nick Rigopoulos | Director Communications | Profile | |
| Allen Davidoff | CEO, Founder | Profile |
Already Invested in XORTX Therapeutics?
The danger of trading XORTX Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XORTX Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XORTX Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XORTX Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.